Skip to main content
Erschienen in: Schweizer Gastroenterologie 1/2020

10.03.2020 | Originalien

Le carcinome hépatocellulaire

verfasst von: Jean-François Dufour

Erschienen in: Schweizer Gastroenterologie | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Résumé

Le carcinome hépatocellulaire est la tumeur maligne la plus fréquente du foie. Il se développe le plus souvent dans le contexte d’une maladie chronique du foie. Les patients à risque d’avoir un carcinome hépatocellulaire doivent être enrôlés dans un programme de surveillance pour que le diagnostic soit fait à un stade précoce. En conséquence les patients avec une cirrhose du foie doivent avoir tous les 6 mois un examen ultrasonographique du foie. Si une lésion apparaît il faut faire des examens diagnostics essentiellement radiologiques. Le traitement du carcinome hépatocellulaire est complexe et doit être conduit par des spécialistes de façon multidisciplinaire. Les patients diagnostiqués à un stade précoce peuvent être guéri. Pour les autres de nouvelles options thérapeutiques existent. L’introduction de traitements immuno-oncologiques offre des chances de survie prolongée.
Literatur
1.
Zurück zum Zitat Lange N, Dufour JF (2019) Changing epidemiology of HCC: How to screen and identify patients at risk? Dig Dis Sci 64:903–909CrossRef Lange N, Dufour JF (2019) Changing epidemiology of HCC: How to screen and identify patients at risk? Dig Dis Sci 64:903–909CrossRef
2.
Zurück zum Zitat Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F (2017) Projections of primary liver cancer to 2030 in 30 countries worldwide Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F (2017) Projections of primary liver cancer to 2030 in 30 countries worldwide
3.
Zurück zum Zitat Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150:835–853CrossRef Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150:835–853CrossRef
4.
Zurück zum Zitat Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G (2016) Hepatocellular carcinoma. Nat Rev Dis Primers 2:16018CrossRef Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G (2016) Hepatocellular carcinoma. Nat Rev Dis Primers 2:16018CrossRef
5.
Zurück zum Zitat Lachenmayer A, Tinguely P, Maurer MH, Frehner L, Knöpfli M, Peterhans M, Weber S et al (2019) Stereotactic image-guided microwave ablation of hepatocellular carcinoma using a computer-assisted navigation system. Liver Int 39:1975–1985CrossRef Lachenmayer A, Tinguely P, Maurer MH, Frehner L, Knöpfli M, Peterhans M, Weber S et al (2019) Stereotactic image-guided microwave ablation of hepatocellular carcinoma using a computer-assisted navigation system. Liver Int 39:1975–1985CrossRef
6.
Zurück zum Zitat Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15:599–616CrossRef Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15:599–616CrossRef
7.
Zurück zum Zitat Inarrairaegui M, Melero I, Sangro B (2018) Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res 24:1518–1524CrossRef Inarrairaegui M, Melero I, Sangro B (2018) Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res 24:1518–1524CrossRef
8.
Zurück zum Zitat Kolly P, Dufour JF (2016) Surveillance for hepatocellular carcinoma in patients with NASH. Diagnostics (Basel) 6:E22CrossRef Kolly P, Dufour JF (2016) Surveillance for hepatocellular carcinoma in patients with NASH. Diagnostics (Basel) 6:E22CrossRef
9.
Zurück zum Zitat Saran U, Humar B, Kolly P, Dufour JF (2016) Hepatocellular carcinoma and lifestyles. J Hepatol 64:203–214CrossRef Saran U, Humar B, Kolly P, Dufour JF (2016) Hepatocellular carcinoma and lifestyles. J Hepatol 64:203–214CrossRef
10.
Zurück zum Zitat Larsson SC, Wolk A (2007) Coffee consumption and risk of liver cancer: a metaanalysis. Gastroenterology 132:1740–1745CrossRef Larsson SC, Wolk A (2007) Coffee consumption and risk of liver cancer: a metaanalysis. Gastroenterology 132:1740–1745CrossRef
11.
Zurück zum Zitat Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C (2013) Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 11:e1411 Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C (2013) Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 11:e1411
12.
Zurück zum Zitat Sang LX, Chang B, Li XH, Jiang M (2013) Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol 13:34CrossRef Sang LX, Chang B, Li XH, Jiang M (2013) Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol 13:34CrossRef
13.
Zurück zum Zitat Lai GY, Weinstein SJ, Albanes D, Taylor PR, McGlynn KA, Virtamo J et al (2013) The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer 109:1344–1351CrossRef Lai GY, Weinstein SJ, Albanes D, Taylor PR, McGlynn KA, Virtamo J et al (2013) The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer 109:1344–1351CrossRef
14.
Zurück zum Zitat Bamia C, Lagiou P, Jenab M, Trichopoulou A, Fedirko V, Aleksandrova K et al (2015) Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer 136:1899–1908CrossRef Bamia C, Lagiou P, Jenab M, Trichopoulou A, Fedirko V, Aleksandrova K et al (2015) Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer 136:1899–1908CrossRef
15.
Zurück zum Zitat Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE (2015) Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 148:118–125, quiz e115CrossRef Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE (2015) Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 148:118–125, quiz e115CrossRef
16.
Zurück zum Zitat Al Hasani F, Knoepfli M, Gemperli A, Kollar A, Banz V, Kettenbach J, Jüni P, Dufour JF (2014) Factors affecting screening for hepatocellular carcinoma. Ann Hepatol 13(2):204–210CrossRef Al Hasani F, Knoepfli M, Gemperli A, Kollar A, Banz V, Kettenbach J, Jüni P, Dufour JF (2014) Factors affecting screening for hepatocellular carcinoma. Ann Hepatol 13(2):204–210CrossRef
Metadaten
Titel
Le carcinome hépatocellulaire
verfasst von
Jean-François Dufour
Publikationsdatum
10.03.2020
Verlag
Springer Vienna
Erschienen in
Schweizer Gastroenterologie / Ausgabe 1/2020
Print ISSN: 2662-7140
Elektronische ISSN: 2662-7159
DOI
https://doi.org/10.1007/s43472-020-00005-z

Weitere Artikel der Ausgabe 1/2020

Schweizer Gastroenterologie 1/2020 Zur Ausgabe

Editorial

Editorial

Editoriale

Editoriale

Éditorial

Éditorial